Source:http://linkedlifedata.com/resource/pubmed/id/15899834
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2005-5-18
|
| pubmed:abstractText |
1'-Acetoxychavicol acetate (ACA) is a component of a traditional Asian condiment obtained from the rhizomes of the commonly used ethno-medicinal plant Languas galanga. Here, we show for the first time that ACA dramatically inhibits the cellular growth of human myeloma cells via the inhibition of nuclear factor kappaB (NF-kappaB) activity. In myeloma cells, cultivation with ACA induced G0-G1 phase cell cycle arrest, followed by apoptosis. Treatment with ACA induced caspase 3, 9, and 8 activities, suggesting that ACA-induced apoptosis in myeloma cells mediates both mitochondrial- and Fas-dependent pathways. Furthermore, we showed that ACA significantly inhibits the serine phosphorylation and degradation of IkappaBalpha. ACA rapidly decreased the nuclear expression of NF-kappaB, but increased the accumulation of cytosol NF-kappaB in RPMI8226 cells, indicating that ACA inhibits the translocation of NF-kappaB from the cytosol to the nucleus. To evaluate the effects of ACA in vivo, RPMI8226-transplanted NOD/SCID mice were treated with ACA. Tumor weight significantly decreased in the ACA-treated mice compared with the control mice. In conclusion, ACA has an inhibitory effect on NF-kappaB, and induces the apoptosis of myeloma cells in vitro and in vivo. ACA, therefore, provides a new biologically based therapy for the treatment of multiple myeloma patients as a novel NF-kappaB inhibitor.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1'-acetoxychavicol acetate,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD95,
http://linkedlifedata.com/resource/pubmed/chemical/Benzyl Alcohols,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/I-kappa B Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/NF-kappa B,
http://linkedlifedata.com/resource/pubmed/chemical/NF-kappaB inhibitor alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase C,
http://linkedlifedata.com/resource/pubmed/chemical/Terpenes,
http://linkedlifedata.com/resource/pubmed/chemical/Tetradecanoylphorbol Acetate
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0008-5472
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
65
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4417-24
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:15899834-Adult,
pubmed-meshheading:15899834-Aged,
pubmed-meshheading:15899834-Antigens, CD95,
pubmed-meshheading:15899834-Apoptosis,
pubmed-meshheading:15899834-Benzyl Alcohols,
pubmed-meshheading:15899834-Caspases,
pubmed-meshheading:15899834-Cell Growth Processes,
pubmed-meshheading:15899834-Cell Line, Tumor,
pubmed-meshheading:15899834-Down-Regulation,
pubmed-meshheading:15899834-Enzyme Activation,
pubmed-meshheading:15899834-Female,
pubmed-meshheading:15899834-Humans,
pubmed-meshheading:15899834-I-kappa B Proteins,
pubmed-meshheading:15899834-Male,
pubmed-meshheading:15899834-Middle Aged,
pubmed-meshheading:15899834-Multiple Myeloma,
pubmed-meshheading:15899834-NF-kappa B,
pubmed-meshheading:15899834-Phosphorylation,
pubmed-meshheading:15899834-Protein Kinase C,
pubmed-meshheading:15899834-Terpenes,
pubmed-meshheading:15899834-Tetradecanoylphorbol Acetate
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.
|
| pubmed:affiliation |
Division of Hematology, Department of Internal Medicine and Pathology, Keio University School of Medicine, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|